Nasal-type NK/T cell lymphoma: clinical features and treatment outcome
Author Information
Author(s): Lee J, Kim W S, Park Y H, Park S H, Park K W, Kang J H, Lee S S, Lee S I, Lee S-H, Kim K, Jung C W, Ahn Y C, Ko Y H, Park K
Primary Institution: Samsung Medical Center, Sungkyunkwan University School of Medicine
Hypothesis
The objective of this study was to investigate clinical features and treatment outcomes in patients with nasal-type NK/T cell lymphoma.
Conclusion
Nasal-type NK/T cell lymphomas showed a poor response to conventional anthracycline-based chemotherapy, indicating a need for innovative therapies to improve survival.
Supporting Evidence
- 60% complete response rate in localized disease after anthracycline-based chemotherapy.
- 0% complete response rate in advanced disease after anthracycline-based chemotherapy.
- Median survival for patients was 7.4 months.
Takeaway
This study looked at a type of cancer called nasal-type NK/T cell lymphoma, which is very aggressive and doesn't respond well to standard treatments, so new therapies are needed.
Methodology
The study included 26 patients diagnosed with nasal-type NK/T cell lymphoma from January 1991 to December 2003, analyzing their clinical features and treatment outcomes.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the small number of patients analyzed.
Limitations
The study is retrospective and has a small sample size, limiting the ability to draw definitive conclusions.
Participant Demographics
The median age at diagnosis was 50 years, with a male to female ratio of 2.3:1.
Statistical Information
P-Value
0.0283
Confidence Interval
95% CI, 0.1, 16.9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website